SCHEMBL10242526

SCHEMBL10242526

Cn1cc(-c2ccc3onc(C(C)(F)c4ccc5ncccc5c4)c3n2)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 18/20 0.59
PDE3B Q13370 4/20 0.54
PDE3A Q14432 4/20 0.54
NQO2 P16083 2/20 0.54
PIP4K2C Q8TBX8 2/20 0.54
DYRK1A Q13627 2/20 0.43
DYRK1B Q9Y463 2/20 0.43
ABL1 P00519 1/20 0.43
MAPK8 P45983 1/20 0.43
MAPK10 P53779 1/20 0.43
MAP3K19 Q56UN5 1/20 0.43
PDE4C Q08493 2/20 0.42
PDE4D Q08499 2/20 0.42
PDE2A O00408 1/20 0.42
CHRM2 P08172 1/20 0.42
PDE4A P27815 1/20 0.42
PDE1A P54750 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE1C Q14123 1/20 0.42
PDE11A Q9HCR9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2699030 0.92 MET (0.70) METPDE3BPDE3ANQO2PIP4K2C
SCHEMBL10242546 0.84 MET (0.82) METPDE3BPDE3ANQO2PIP4K2C
SCHEMBL10242522 0.80 MET (0.84) METPDE3BPDE3ANQO2PIP4K2C
SCHEMBL10242536 0.78 MET (0.55) METPDE3BPDE3ANQO2PIP4K2C
SCHEMBL10242527 0.77 MET (0.54) MET
SCHEMBL9910485 0.74 MET (1.00) METPDE3BPDE3ANQO2PIP4K2C
SCHEMBL9910484 0.73 MET (1.00) METPDE3BPDE3ANQO2PIP4K2C
SCHEMBL1658513 0.72 MET (0.78) METPDE3BPDE3ANQO2PIP4K2C
Jnj-38877605 SCHEMBL182199 0.70 MET (1.00) METPDE3BPDE3ANQO2PIP4K2C
Jnj-38877605 SCHEMBL30028214 0.70 MET (1.00) METPDE3BPDE3ANQO2PIP4K2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120107275-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120107275-A1 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE HGF, HGFAC, MET MET 3/4885PDE3B 1730/4885PDE3A 1765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.